Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study

References

• Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363:640–652.
   PubMed Web of Science ®Google Scholar
• Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28:4199–4206.
   PubMed Web of Science ®Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374:2419–2429.
   PubMed Web of Science ®Google Scholar
• Gilbert ES, Stovall M, Gospodarowicz M, et al. Lung cancer after treatment for Hodgkin’s disease: focus on radiation effects. Radiat Res. 2003;159:161–173.
   PubMed Web of Science ®Google Scholar
• Krul IM, Opstal-van Winden AWJ, Aleman BMP, et al. Breast cancer risk after radiation therapy for Hodgkin lymphoma: influence of gonadal hormone exposure. Int J Radiat Oncol Biol Phys. 2017;99:843–853.
   PubMed Web of Science ®Google Scholar
• Moignier A, Broggio D, Derreumaux S, et al. Coronary stenosis risk analysis following Hodgkin lymphoma radiotherapy: a study based on patient specific artery segments dose calculation. Radiother Oncol. 2015;117:462–472.
   Web of Science ®Google Scholar
• Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst. 2002;94:182–192.
   PubMed Web of Science ®Google Scholar
• van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2016;34:235–243.
   PubMed Web of Science ®Google Scholar
• Cutter DJ, Schaapveld M, Darby SC, et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst. 2015;107:djv008.
   PubMedGoogle Scholar
• Maraldo MV, Giusti F, Vogelius IR, et al. Cardiovascular disease after treatment for Hodgkin’s lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematol. 2015;2:e492–e502.
   PubMed Web of Science ®Google Scholar
• Conway JL, Connors JM, Tyldesley S, et al. Secondary breast cancer risk by radiation volume in women with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2017;97:35–41.
   PubMed Web of Science ®Google Scholar
• De Bruin ML, Sparidans J, van’t Veer MB, et al. Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. JCO. 2009;27:4239–4246.
   PubMed Web of Science ®Google Scholar
• Patel CG, Michaelson E, Chen YH, et al. Reduced mortality risk in the recent era in early-stage Hodgkin lymphoma patients treated with radiation therapy with or without chemotherapy. Int J Radiat Oncol Biol Phys. 2018;100:498–506.
   PubMed Web of Science ®Google Scholar
• Specht L. Radiotherapy for Hodgkin lymphoma: reducing toxicity while maintaining efficacy. Cancer J (Sudbury, Mass). 2018;24:237–243.
   PubMed Web of Science ®Google Scholar
• Niemierko A, Urie M, Goitein M. Optimization of 3d radiation therapy with both physical and biological end points and constraints. Int J Radiat Oncol Biol Phys. 1992;23:99–108.
   PubMed Web of Science ®Google Scholar
• Brahme A, Nilsson J, Belkic D. Biologically optimized radiation therapy. Acta Oncol. 2001;40:725–734.
   PubMed Web of Science ®Google Scholar
• Markov K, Schinkel C, Stavreva N, et al. Reverse mapping of normal tissue complication probabilities onto dose volume histogram space: the problem of randomness of the dose volume histogram sampling. Med Phys. 2006;33:3435–3443.
   PubMed Web of Science ®Google Scholar
• Peñagarícano JA, Papanikolaou N, Wu C, et al. An assessment of biologically-based optimization (BORT) in the IMRT era. Med Dosim. 2005;30:12–19.
   PubMed Web of Science ®Google Scholar
• Qi XS, Semenenko VA, Li XA. Improved critical structure sparing with biologically based IMRT optimization. Med Phys. 2009;36:1790–1799.
   PubMed Web of Science ®Google Scholar
• Rechner LA, Eley JG, Howell RM, et al. Risk-optimized proton therapy to minimize radiogenic second cancers. Phys Med Biol. 2015;60:3999–4013.
   PubMed Web of Science ®Google Scholar
• Witte MG, van der Geer J, Schneider C, et al. IMRT optimization including random and systematic geometric errors based on the expectation of TCP and NTCP. Med Phys. 2007;34:3544–3555.
   PubMed Web of Science ®Google Scholar
• Mihaylov IB, Fatyga M, Bzdusek K, et al. Biological optimization in volumetric modulated arc radiotherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2012;82:1292–1298.
   PubMed Web of Science ®Google Scholar
• Sanchez-Nieto B, Romero-Exposito M, Terron JA, et al. Uncomplicated and cancer-free control probability (UCFCP): a new integral approach to treatment plan optimization in photon radiation therapy. Phys Med. 2017;42:277–284.
   PubMed Web of Science ®Google Scholar
• Kierkels RGJ, Korevaar EW, Steenbakkers R, et al. Direct use of multivariable normal tissue complication probability models in treatment plan optimisation for individualised head and neck cancer radiotherapy produces clinically acceptable treatment plans. Radiother Oncol. 2014;112:430–436.
   PubMed Web of Science ®Google Scholar
• Kierkels RGJ, Wopken K, Visser R, et al. Multivariable normal tissue complication probability model-based treatment plan optimization for grade 2-4 dysphagia and tube feeding dependence in head and neck radiotherapy. Radiother Oncol. 2016;121:374–380.
   PubMed Web of Science ®Google Scholar
• Corwin D, Holdsworth C, Rockne RC, et al. Toward patient-specific, biologically optimized radiation therapy plans for the treatment of glioblastoma. PloS One. 2013;8:e79115.
   PubMed Web of Science ®Google Scholar
• Ferreira BC, Mavroidis P, Adamus-Górka M, et al. The impact of different dose–response parameters on biologically optimized IMRT in breast cancer. Phys Med Biol. 2008;53:2733–2752.
   PubMed Web of Science ®Google Scholar
• Thomas EE, Ten Haken RK, Chapet O, et al. The use of biological parameters (EUD and NTCP) in IMRT optimization and its impact on the maximum safe dose deliverable to intrahepatic tumors. Int J Radiat Oncol Biol Phys. 2004;60:S179–S180.
   Web of Science ®Google Scholar
• Brodin NP, Maraldo MV, Aznar MC, et al. Interactive decision-support tool for risk-based radiation therapy plan comparison for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2014;88:433–445.
   PubMed Web of Science ®Google Scholar
• Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89:854–862.
   PubMed Web of Science ®Google Scholar
• Maraldo MV, Brodin P, Aznar MC, et al. Doses to carotid arteries after modern radiation therapy for Hodgkin lymphoma: is stroke still a late effect of treatment?. Int J Radiat Oncol Biol Phys. 2013;87:297–303.
   PubMedGoogle Scholar
• Voong KR, McSpadden K, Pinnix CC, et al. Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma. Radiat Oncol. 2014;9:94.
   PubMed Web of Science ®Google Scholar
• Modiri A, Stick LB, Rice SR, et al. Individualized estimates of overall survival in radiation therapy plan optimization – a concept study. Med Phys. 2018;45:5332–5342.
   PubMed Web of Science ®Google Scholar
• Eberhart R, Kennedy J. editors. A new optimizer using particle swarm theory. Proceedings of the Sixth International Symposium on Micro Machine and Human Science, 1995 (MHS ’95); 1995 Oct 4–6. 1995.
   Google Scholar
• Eberhart R, Shi Y, Kennedy J. Swarm Intelligence. The Morgan Kaufmann Series in Artificial Intelligence. San Francisco (CA): Morgan Kaufmann; 2001.
   Google Scholar
• Li Y, Yao D, Yao J, et al. A particle swarm optimization algorithm for beam angle selection in intensity-modulated radiotherapy planning. Phys Med Biol. 2005;50:3491–3514.
   PubMed Web of Science ®Google Scholar
• Modiri A, Gu X, Hagan A, et al. Radiotherapy planning using an improved search strategy in particle swarm optimization. IEEE Trans Biomed Eng. 2016;PP:1–1.
   Google Scholar
• Yang J, Zhang P, Zhang L, et al. Particle swarm optimizer for weighting factor selection in intensity-modulated radiation therapy optimization algorithms. Physica Med. 2017;33:136–145.
   PubMed Web of Science ®Google Scholar
• Herbst C, Rehan FA, Brillant C, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review. Haematologica. 2010;95:494–500.
   PubMed Web of Science ®Google Scholar
• Sovik A, Ovrum J, Olsen DR, et al. On the parameter describing the generalised equivalent uniform dose (gEUD) for tumours. Phys Med. 2007;23:100–106.
   PubMedGoogle Scholar
• Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys. 1997;24:103–110.
   PubMed Web of Science ®Google Scholar
• Brodin NP, Vogelius IR, Maraldo MV, et al. Life years lost–comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale. Cancer. 2012;118:5432–5440.
   PubMed Web of Science ®Google Scholar
• CDC. Centers for Disease Control and Prevention – relative cancer survival. Available from: https://www.cdc.gov/cancer/npcr/uscs/technical_notes/stat_methods/survival.htm
   Google Scholar
• Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003;290:465–475.
   PubMed Web of Science ®Google Scholar
• CDC. Centers for Disease Control and Prevention – age-adjusted death rates for selected causes of death, by sex, race, and Hispanic origin. Available from: https://www.cdc.gov/nchs/data/hus/2017/017.pdf
   Google Scholar
• CDC. Centers for Disease Control and Prevention – death rates for diseases of heart, by sex, race, Hispanic origin, and age. Available from: https://www.cdc.gov/nchs/data/hus/2017/022.pdf
   Google Scholar
• NIH. SEER Cancer Statistics Review 1975–2013 – Table 15.19 – cancer of the lung and bronchus in males. National Cancer Institute Surveillance, Epidemiology and End Results Program. Available from: https://seercancergov/csr/1975_2013/browse_csrphp?sectionSEL=15&pageSEL=sect_15_table19html
   Google Scholar
• NIH. SEER Cancer Statistics Review 1975–2013 – Table 15.20 – cancer of the lung and bronchus in females. National Cancer Institute Surveillance, Epidemiology and End Results Program. Available from: https://seercancergov/csr/1975_2013/browse_csrphp?sectionSEL=15&pageSEL=sect_15_table20html
   Google Scholar
• NIIH. SEER Cancer Stat Facts: lung and bronchus cancer. National Cancer Institute Surveillance, Epidemiology and End Results Program. Available from: https://seercancergov/statfacts/html/lungbhtml
   Google Scholar
• NIH. SEER Cancer Statistics Review 1975–2013, Table 4.17, cancer of female breast (invasive). National Cancer Institute Surveillance, Epidemiology and End Results Program. Available from: https://seercancergov/csr/1975_2013/browse_csrphp?sectionSEL=4&pageSEL=sect_04_table17html
   Google Scholar
• NIH. SEER Cancer Stat Facts: female breast cancer. National Cancer Institute Surveillance, Epidemiology and End Results Program. Available from: https://seercancergov/statfacts/html/breasthtml
   Google Scholar
• Alber M, Thorwarth D. Multi-modality functional image guided dose escalation in the presence of uncertainties. Radiother Oncol. 2014;111:354–359.
   PubMed Web of Science ®Google Scholar